Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04768296
Title Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors EMD Serono Research & Development Institute, Inc.
Indications

Advanced Solid Tumor

lung small cell carcinoma

Therapies

Berzosertib + Topotecan

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.